(REUTERS) Canada’s health regulator is launching a probe into Pfizer’s arthritis drug, Xeljanz, after a trial by the company identified an increased risk of serious heart-related issues and cancer in the participants. The trial investigated the long-term safety of Xeljanz at two doses in patients with rheumatoid arthritis, who... Read more
Pfizer missed EU vaccine supply goal by 30 per cent, officials say
COVID-19HealthInternationalNews Feb 17, 2021
Pfizer delivered about one third fewer doses to the EU than was promised by this point, according to EU officials. This will put extra strain on the EU, which has already faced delays from AstraZeneca and Moderna.
Read more
